We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study
Introduction : Recent studies have demonstrated that first-line treatment with gefitinib , an epidermal growth factor receptor (EFGR)–targeted tyrosine kinase inhibitor , is significantly superior to st and ard chemotherapy for advanced non – small-cell lung cancer ( NSCLC ) harboring EGFR sensitive mutations . Meanwhile , the efficacy of gefitinib therapy among elderly population s diagnosed with EGFR-mutated NSCLC has not yet been eluci date d. The purpose of this study was to investigate the efficacy and feasibility of gefitinib for chemotherapy-naive patients aged 75 or older with NSCLC harboring EGFR mutations ; generally , these patients have no indication for treatment with platinum doublets . Methods : Chemotherapy-naive patients aged 75 years or older with performance status 0 to 1 and advanced NSCLC harboring EGFR mutations , as determined by the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method , were enrolled . The enrolled patients received 250 mg/day of gefitinib orally . Results : Between January 2008 and May 2009 , 31 patients were enrolled , all of whom were eligible . The median age was 80 ( range , 75–87 ) years . Twenty-five patients ( 81 % ) were women , and 30 patients ( 97 % ) had adenocarcinoma . The overall response rate was 74 % ( 95 % confidence interval , 58%–91 % ) , and the disease control rate was 90 % . The median progression-free survival was 12.3 months . The common adverse events were rash , diarrhea , and liver dysfunction . One treatment-related death because of interstitial lung disease occurred . Conclusions : This is the first study that verified safety and efficacy of first-line treatment with gefitinib in elderly patients having advanced NSCLC with EGFR mutation . Considering its strong antitumor activity and mild toxicity , first-line gefitinib may be preferable to st and ard chemotherapy for this population
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV